Latest Intelligence on Pharmaceuticals and Healthcare in Russia

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Verta/SciClone: new drug could limit TB spread

According to preliminary results, Russian pharma company Verta's new immune system enhancing drug may have a significant impact on TB contagion. Although the treatment regime is arduous, involving five daily injections, there could be a significant market for SCV-07 in locations where Directly Observed Treatment can be implemented.

Published By Datamonitor
01 Oct 2002
CommentWire
CommentWire

Novelos Therapeutics: fast track presents new opportunities

Having received marketing approval in Russia and performed well in phase I/II trials, Novelos Therapeutics' NOV-002 has now been granted FDA fast track designation in lung cancer. This means a new drug application submission can occur on a rolling basis, which should speed up the approval process. However, Novelos should secure an experienced marketing partner to maximize on NOV-002's potential.

Published By Datamonitor
08 Aug 2006
Expert View
Expert View

Big Pharma rushing for foothold in emerging markets despite challenges

Faced with dwindling growth rates in the US and Europe, drug companies are turning their attention towards emerging pharmaceutical markets where recent economic booms have fuelled double-digit growth. However, although the patient potential of these countries is enormous, foreign pharmaceutical companies are currently tapping into only a fraction of the market.

Published By Datamonitor
13 Mar 2008
Expert View
Expert View

Antigenics's Oncophage approved for use in Russia

Oncophage has received Russian approval for the treatment of non-metastatic, intermediate-risk renal cell carcinoma patients. However, the vaccine is unlikely to be approved in the US and EU based on the same data. Though a significant milestone for Antigenics, the company will need to gain approval in the lucrative US and major EU countries in order to increase Oncophage's commercial potential.

Published By Datamonitor
09 Apr 2008
Expert View
Expert View

Abbott's flu vaccine business may represent a good deal for acquisitive drug makers

According to media reports, pharmaceutical company Abbott Laboratories is looking to auction off its influenza vaccine business in a deal that could be worth up to $600m. Abbott's established link to the Russian flu market and its advanced cell-based technology make the business an attractive prospect for would-be buyers, which may include the likes of GlaxoSmithKline and MedImmune.

Published By Datamonitor
29 Jun 2010
CommentWire
CommentWire

Merck Serono: cladribine's failure is a big setback for the company, not MS patients

Swiss drugmaker Merck Serono has announced the discontinuation of additional trials for cladribine and the withdrawal of the product from the Russian and Australian markets, showing that the firm has decided to cut its losses and accept a costly failure. The decision to discontinue a once potentially blockbusting therapy is a huge setback for Merck and its multiple sclerosis portfolio.

Published By Datamonitor
22 Jun 2011

« | 1 | » »|

No help is available.